iSpecimen (NASDAQ:ISPC – Get Free Report) and GeneDx (NASDAQ:WGS – Get Free Report) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, analyst recommendations, profitability, earnings and risk.
Insider and Institutional Ownership
13.6% of iSpecimen shares are held by institutional investors. Comparatively, 61.7% of GeneDx shares are held by institutional investors. 12.2% of iSpecimen shares are held by company insiders. Comparatively, 29.6% of GeneDx shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Analyst Ratings
This is a breakdown of current ratings for iSpecimen and GeneDx, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| iSpecimen | 1 | 0 | 0 | 0 | 1.00 |
| GeneDx | 1 | 3 | 7 | 0 | 2.55 |
Valuation and Earnings
This table compares iSpecimen and GeneDx”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| iSpecimen | $9.29 million | 0.79 | -$12.50 million | ($9.51) | -0.08 |
| GeneDx | $305.45 million | 13.01 | -$52.29 million | $0.09 | 1,536.67 |
iSpecimen has higher earnings, but lower revenue than GeneDx. iSpecimen is trading at a lower price-to-earnings ratio than GeneDx, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
iSpecimen has a beta of 1.77, meaning that its share price is 77% more volatile than the S&P 500. Comparatively, GeneDx has a beta of 2, meaning that its share price is 100% more volatile than the S&P 500.
Profitability
This table compares iSpecimen and GeneDx’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| iSpecimen | -172.48% | -395.15% | -121.72% |
| GeneDx | 0.52% | 20.22% | 11.89% |
Summary
GeneDx beats iSpecimen on 13 of the 14 factors compared between the two stocks.
About iSpecimen
iSpecimen Inc. provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with biospecimens available in healthcare provider organizations worldwide. Its cloud-based technology enables scientists to search for specimens and patients across a network of hospitals, clinics, private practice groups, laboratories, blood centers, biobanks, clinical research sites, and cadaveric donation centers. The company develops and operates iSpecimen Marketplace, a proprietary online marketplace platform that connects medical researchers who need access to subjects, samples, and data with hospitals, laboratories, and other organizations who have access to them. It serves biopharmaceutical companies, in vitro diagnostic companies, and government/academic institutions. iSpecimen Inc. was incorporated in 2009 and is headquartered in Lexington, Massachusetts.
About GeneDx
GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights. It provides genetic diagnostic tests, screening solutions, and information with a focus on pediatrics, rare diseases for children and adults, and hereditary cancer screening. GeneDx Holdings Corp. was founded in 2017 and is headquartered in Stamford, Connecticut.
Receive News & Ratings for iSpecimen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iSpecimen and related companies with MarketBeat.com's FREE daily email newsletter.
